Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in RET-fusion Non Small Cell Lung Cancer
View Full LandscapeTarget Indication
RET-fusion Non Small Cell Lung Cancer
Clinical Trial
NCT04222972Last updated: 2/9/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Gavreto
Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.